Lung Cancer Therapy - Global Strategic Business Report

The global market for Lung Cancer Therapy was estimated at US$38.2 Billion in 2024 and is projected to reach US$77.5 Billion by 2030, growing at a CAGR of 12.5% from 2024 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions. The report includes the most recent global tariff developments and how they impact the Lung Cancer Therapy market.

Global Lung Cancer Therapy Market - Key Trends & Drivers Summarized

Why Is Lung Cancer Therapy Undergoing a Major Transformation in the Modern Medical Landscape?

Lung cancer therapy has entered a period of rapid transformation, driven by advancements in medical science, early detection strategies, and a deeper understanding of cancer biology. As one of the most prevalent and deadly forms of cancer worldwide, lung cancer has long presented challenges due to its late-stage diagnosis and aggressive nature. Historically dominated by surgery, chemotherapy, and radiation, treatment approaches are now evolving to include targeted therapies, immunotherapies, and personalized medicine. Non-small cell lung cancer (NSCLC), which accounts for the majority of lung cancer cases, is now being treated based on specific genetic mutations and biomarkers such as EGFR, ALK, and ROS1, allowing for more precise and effective interventions. Meanwhile, small cell lung cancer (SCLC), known for its rapid progression, is also seeing improvements in therapeutic options through the use of combination regimens and novel agents. Multidisciplinary care involving oncologists, pulmonologists, radiologists, and pathologists is becoming the standard, facilitating better decision-making and individualized care plans. Advances in imaging technologies, liquid biopsies, and molecular profiling are enabling earlier and more accurate diagnoses, increasing the potential for successful outcomes. Patient advocacy and global awareness campaigns are also driving earlier screenings and greater access to treatment, especially in high-risk populations such as smokers and individuals with occupational exposure. With continuous investment in research and a pipeline full of innovative therapies, lung cancer treatment is moving toward a more hopeful future where outcomes are steadily improving and long-term remission becomes an increasingly realistic goal.

How Are Targeted Therapies and Immunotherapies Revolutionizing the Treatment of Lung Cancer?

The rise of targeted therapies and immunotherapies is revolutionizing lung cancer treatment by offering tailored approaches that address the molecular drivers of the disease rather than relying on broadly toxic systemic treatments. Targeted therapies work by inhibiting specific genetic mutations that fuel cancer growth, such as EGFR mutations or ALK rearrangements in NSCLC patients. These therapies, including tyrosine kinase inhibitors (TKIs), have demonstrated superior efficacy and fewer side effects compared to traditional chemotherapy. Additionally, advancements in next-generation sequencing allow for the identification of rare mutations, expanding treatment eligibility and improving precision in therapy selection. Immunotherapies, particularly immune checkpoint inhibitors like PD-1 and PD-L1 inhibitors, are reshaping the landscape by enabling the body's immune system to recognize and destroy cancer cells. These agents have significantly extended survival rates in patients with advanced disease and are increasingly being used in combination with chemotherapy or as maintenance therapy following initial response. The introduction of combination immunotherapy regimens is yielding impressive clinical results, particularly in tumors with high mutational burdens or immune responsiveness. Research is also focusing on overcoming resistance to targeted therapies and enhancing immune responses through novel agents such as cancer vaccines, adoptive T-cell therapy, and bispecific antibodies. The integration of these innovative approaches is not only prolonging survival but also improving the quality of life for many lung cancer patients. As regulatory agencies expedite approvals for promising treatments, and as real-world data continues to support their use, the role of targeted and immune-based therapies in lung cancer care will only continue to grow.

What Emerging Trends in Diagnostics and Patient Management Are Influencing Lung Cancer Therapy?

The evolution of diagnostics and patient management strategies is playing a pivotal role in shaping the future of lung cancer therapy, enhancing early detection, treatment personalization, and overall patient outcomes. One of the most impactful trends is the increased use of low-dose computed tomography (LDCT) screening in high-risk populations, which has proven effective in identifying lung cancer at earlier, more treatable stages. Molecular diagnostics are now routine in clinical settings, with tests that profile tumors for actionable mutations using tissue or blood samples, a practice known as liquid biopsy. These non-invasive tests are enabling ongoing monitoring of disease progression and treatment response, allowing for timely adjustments to therapy. Artificial intelligence and machine learning algorithms are being integrated into imaging and pathology workflows to improve diagnostic accuracy and reduce time to treatment. Patient-centric care models are also emerging, emphasizing shared decision-making, psychological support, and multidisciplinary coordination. Telemedicine and digital health tools are expanding access to care, particularly in remote or underserved areas, while also supporting continuous monitoring of patient symptoms and treatment adherence. Clinical decision support systems are assisting healthcare providers in selecting optimal therapies based on individual patient profiles and the latest evidence-based guidelines. Enhanced focus on survivorship and long-term care is addressing issues such as fatigue, lung function, and secondary malignancies, ensuring that quality of life remains a central aspect of therapy planning. Together, these innovations in diagnostics and care management are supporting a more proactive, precise, and patient-centered approach to lung cancer treatment.

What Are the Main Drivers Behind the Global Growth of the Lung Cancer Therapy Market?

The growth in the global lung cancer therapy market is driven by a convergence of factors related to technological innovation, increasing disease burden, improved healthcare infrastructure, and rising demand for personalized care. A key driver is the rising incidence of lung cancer worldwide, fueled by aging populations, continued tobacco use in certain regions, environmental pollution, and occupational hazards. This growing patient base is prompting both public and private sectors to invest heavily in oncology research, diagnostics, and treatment facilities. Another major factor is the accelerating development and commercialization of novel therapies, including targeted drugs and immunotherapies, which offer improved outcomes and are rapidly being adopted across clinical settings. Regulatory bodies are streamlining approval processes for breakthrough treatments, often providing fast-track designations and orphan drug status to expedite market entry. Advancements in biomarker research and genomics are enabling the design of highly specific therapies that improve efficacy and reduce adverse effects, aligning with global trends in precision medicine. In addition, expanding access to healthcare services in emerging economies is increasing treatment uptake, supported by government funding and international health initiatives. Pharmaceutical collaborations and mergers are strengthening research pipelines and broadening treatment portfolios. Furthermore, growing awareness among patients about screening and treatment options is enhancing early diagnosis rates and treatment initiation. As clinical guidelines evolve to incorporate cutting-edge therapies and as healthcare providers embrace integrated care models, the lung cancer therapy market is poised for sustained and substantial growth across both developed and developing regions.

Scope Of Study:

The report analyzes the Lung Cancer Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments: Therapy (Noninvasive Therapy, Minimally Invasive Therapy); Indication (Non-Small Cell Lung Cancer, Small Cell Lung Cancer); End-Use (Hospitals End-Use, Oncology Clinics End-Use, Research Centers End-Use)

Geographic Regions/Countries: World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Key Insights:

• Market Growth: Understand the significant growth trajectory of the Noninvasive Therapy segment, which is expected to reach US$51.2 Billion by 2030 with a CAGR of a 14.2%. The Minimally Invasive Therapy segment is also set to grow at 9.6% CAGR over the analysis period.
• Regional Analysis: Gain insights into the U.S. market, estimated at $10.4 Billion in 2024, and China, forecasted to grow at an impressive 17.1% CAGR to reach $16.5 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

• Detailed Market Analysis: Access a thorough analysis of the Global Lung Cancer Therapy Market, covering all major geographic regions and market segments.
• Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
• Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Lung Cancer Therapy Market.
• Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

• How is the Global Lung Cancer Therapy Market expected to evolve by 2030?
• What are the main drivers and restraints affecting the market?
• Which market segments will grow the most over the forecast period?
• How will market shares for different regions and segments change by 2030?
• Who are the leading players in the market, and what are their prospects?

Report Features:

• Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2024 to 2030.
• In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
• Company Profiles: Coverage of players such as AbbVie, Inc., Amgen Inc., AstraZeneca Plc, Bayer AG, Boehringer Ingelheim International GmbH and more.
• Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 41 companies featured in this Lung Cancer Therapy market report include:

• AbbVie, Inc.
• Amgen Inc.
• AstraZeneca Plc
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company, Limited
• Eli Lilly and Company
• Gilead Sciences / Kite Pharma
• GlaxoSmithKline plc (GSK)
• Hoffmann-La Roche Ltd (Roche)
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck & Co., Inc.
• Moderna Therapeutics
• Novartis AG
• Pfizer Inc.
• Sanofi S.A.
• Seagen Inc.
• Takeda Pharmaceutical Company Limited
• Teva Pharmaceutical Industries Ltd.

This edition integrates the latest global trade and economic shifts as of June 2025 into comprehensive market analysis. Key updates include:

• Tariff and Trade Impact: Insights into global tariff negotiations across 180+ countries, with analysis of supply chain turbulence, sourcing disruptions, and geographic realignment. Special focus on 2025 as a pivotal year for trade tensions, including updated perspectives on the Trump-era tariffs.
• Adjusted Forecasts and Analytics: Revised global and regional market forecasts through 2030, incorporating tariff effects, economic uncertainty, and structural changes in globalization. Includes segmentation by product, technology, type, material, distribution channel, application, and end-use, with historical analysis since 2015.
• Strategic Market Dynamics: Evaluation of revised market prospects, regional outlooks, and key economic indicators such as population and urbanization trends.
• Innovation & Technology Trends: Latest developments in product and process innovation, emerging technologies, and key industry drivers shaping the competitive landscape.
• Competitive Intelligence: Updated global market share estimates for 2025, competitive positioning of major players (Strong/Active/Niche/Trivial), and refined focus on leading global brands and core players.
• Expert Insight & Commentary: Strategic analysis from economists, trade experts, and domain specialists to contextualize market shifts and identify emerging opportunities.
• Complimentary Update: Buyers receive a free July 2025 update with finalized tariff impacts, new trade agreement effects, revised projections, and expanded country-level coverage.